Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Dose Study of MK-1942 in Healthy Japanese Adults
jRCT2031210214Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-1942 in Alzheimer's disease (AD) and treatment-resistant depression (TRD) (8 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability - single dose and Safety and tolerability - multiple dose. Started Aug 2021; status: completed.
02
Drugs
MK-1942
03
Conditions
Alzheimer's disease (AD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on jRCT2031210214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210214.